Related Experiment Videos
Follicular large-cell lymphoma: intermediate or low grade?
N L Bartlett1, M Rizeq, R F Dorfman
1Department of Medicine, Stanford University School of Medicine, CA.
Summary
Anthracycline-based chemotherapy, particularly with doxorubicin and cyclophosphamide, offers sustained remissions for follicular large-cell lymphoma. This intermediate-grade lymphoma can be treated with curative intent.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Follicular large-cell (FLC) lymphoma is an intermediate-grade non-Hodgkin lymphoma.
- Treatment strategies and prognostic factors require ongoing evaluation to optimize patient outcomes.
Purpose of the Study:
- To assess the efficacy of anthracycline-based chemotherapy for FLC lymphoma.
- To identify key prognostic factors influencing patient survival and disease progression.
- To determine the utility of the International Prognostic Factors Index in this patient cohort.
Main Methods:
- Retrospective analysis of 96 FLC lymphoma patients treated between 1969 and 1991.
- Comparison of outcomes based on treatment modalities: doxorubicin/cyclophosphamide chemotherapy, other chemotherapy, radiotherapy, or no initial therapy.
- Evaluation of prognostic factors including disease stage, histology, performance status, and International Prognostic Factors Index.
Main Results:
- Overall survival rates at 5 and 10 years were 75% and 54%, with freedom from progression (FFP) rates of 53% and 42%, respectively.
- Doxorubicin/cyclophosphamide chemotherapy demonstrated superior 10-year FFP (55% vs. 25%) and overall survival (65% vs. 42%) compared to other regimens.
- Multivariate analysis identified discordant lymphoma and non-anthracycline/cyclophosphamide chemotherapy as predictors of worse outcomes; poor performance status and diffuse histology also impacted survival.
Conclusions:
- Standard anthracycline-based chemotherapy leads to sustained remissions in FLC lymphoma, indicated by a plateau in freedom from progression.
- FLC lymphoma should be managed as an intermediate-grade lymphoma with a focus on curative treatment strategies.